-
A.
Stueven,
Antonin
Kayser,
C.
Wetz,
H.
Amthauer,
A.
Wree,
F.
Tacke,
B.
Wiedenmann,
C.
Roderburg,
H.
Jann
(2019)
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
International Journal of Molecular Sciences, 20
-
Jianqing
Xu,
L.
Shen,
C.
Bai,
Jiuqiang
Li,
Zongmei
Zhou,
Xianjun
Yu,
Z.
Li,
E.
Li,
Xianglin
Yuan,
Y.
Chi,
Y.
Yin,
W.
Lou,
N.
Xu,
Y.
Bai,
Tao
Zhang,
D.
Xiu,
Xuehao
Wang,
S.
Fan,
W.
Su
(2020)
1156O Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Annals of Oncology
-
B.
Oronsky,
P.
Ma,
D.
Morgensztern,
C.
Carter
(2017)
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Neoplasia (New York, N.Y.), 19
-
J.
Pozas,
M.
Román,
T.
Alonso-Gordoa,
M.
Pozas,
L.
Caracuel,
A.
Carrato,
J.
Molina-Cerrillo
(2019)
Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms
International Journal of Molecular Sciences, 20
-
C.
Chamberlain,
M.
German,
Katherine
Yang,
Jason
Wang,
H.
VanBrocklin,
Melanie
Regan,
K.
Shokat,
Gregory
Ducker,
Grace
Kim,
B.
Hann,
D.
Donner,
R.
Warren,
A.
Venook,
E.
Bergsland,
Danny
Lee,
Yucheng
Wang,
E.
Nakakura
(2018)
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Molecular Cancer Therapeutics, 17
-
(2012)
Deficiency of the macrophage growth factor Therapeutic Advances in Medical Oncology 13 12 journals.sagepub.com/home/tam CSF-1 disrupts pancreatic neuroendocrine tumor development
-
Ryohei
Shimoyama,
S.
Hijioka,
N.
Mizuno,
G.
Ogawa,
T.
Kataoka,
H.
Katayama,
N.
Machida,
Y.
Honma,
N.
Boku,
T.
Hamaguchi,
H.
Fukuda,
M.
Terashima,
Y.
Kanemitsu,
J.
Furuse
(2020)
Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET stud
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
-
A.
Angelousi,
K.
Kamp,
Maria
Kaltsatou,
D.
O’Toole,
G.
Kaltsas,
W.
Herder
(2017)
Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments
Neuroendocrinology, 105
-
M.
Cives,
E.
Pelle’,
J.
Strosberg
(2020)
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
Journal of Clinical Medicine, 9
-
Jianming
Xu,
L.
Shen,
C.
Bai,
Wei
Wang,
Jie
Li,
Xianjun
Yu,
Zhiping
Li,
E.
Li,
Xianglin
Yuan,
Y.
Chi,
Yongmei
Yin,
W.
Lou,
N.
Xu,
Y.
Bai,
Tao
Zhang,
D.
Xiu,
Xiuwen
Wang,
Ying
Yuan,
Jia
Chen,
S.
Qin,
R.
Jia,
Ming
Lu,
Yue-juan
Cheng,
Zhiwei
Zhou,
Jing
Li,
James
He,
W.
Su
(2020)
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet. Oncology
-
T.
Batchelor,
A.
Sorensen,
E.
Tomaso,
Wei-Ting
Zhang,
D.
Duda,
K.
Cohen,
K.
Kozak,
D.
Cahill,
P.
Chen,
M.
Zhu,
M.
Ancukiewicz,
M.
Mrugala,
S.
Plotkin,
J.
Drappatz,
D.
Louis,
P.
Ivy,
D.
Scadden,
T.
Benner,
J.
Loeffler,
P.
Wen,
R.
Jain
(2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer cell, 11 1
-
Y.
Jiao,
C.
Shi,
B.
Edil,
R.
Wilde,
D.
Klimstra,
A.
Maitra,
R.
Schulick,
Laura
Tang,
elliot
fishman,
M.
Choti,
V.
Velculescu,
L.
Diaz,
B.
Vogelstein,
K.
Kinzler,
R.
Hruban,
N.
Papadopoulos
(2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Science, 331
-
J.
Hofland,
G.
Kaltsas,
W.
Herder
(2020)
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Endocrine Reviews, 41
-
S.
Adant,
Girish
Shah,
J.
Beauregard
(2019)
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging, 47
-
J.
Valle,
I.
Borbath,
B.
Rosbrook,
Kathrine
Fernandez,
E.
Raymond
(2019)
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Future oncology, 15 11
-
M.
Cives,
J.
Strosberg
(2018)
Gastroenteropancreatic Neuroendocrine Tumors
CA: A Cancer Journal for Clinicians, 68
-
J.
Reubi,
A.
Schonbrunn
(2013)
Illuminating somatostatin analog action at neuroendocrine tumor receptors.
Trends in pharmacological sciences, 34 12
-
L.
Mestier,
T.
Walter,
C.
Evrard,
P.
Boissieu,
O.
Hentic,
J.
Cros,
D.
Tougeron,
C.
Lombard-Bohas,
V.
Rebours,
P.
Hammel,
P.
Ruszniewski
(2019)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Neuroendocrinology, 110
-
Alberto
Bongiovanni,
C.
Liverani,
F.
Foca,
V.
Fausti,
G.
Menna,
L.
Mercatali,
A.
Vita,
N.
Riva,
S.
Calpona,
G.
Miserocchi,
C.
Spadazzi,
C.
Cocchi,
T.
Ibrahim
(2020)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “Real-World” Data Analysis
Neuroendocrinology, 111
-
I.
Keklikoglou,
Ece
Kadioglu,
Stefan
Bissinger,
B.
Langlois,
Axel
Bellotti,
G.
Orend,
C.
Ries,
Michele
Palma
(2018)
Periostin Limits Tumor Response to VEGFA Inhibition.
Cell reports, 22 10
-
(2020)
AACR2020: a phase I trial of surufatinib plus toripalimab in patients with advanced solid tumor
-
Jianming
Xu,
L.
Shen,
Zhiwei
Zhou,
Jie
Li,
C.
Bai,
Y.
Chi,
Zhiping
Li,
N.
Xu,
E.
Li,
Tianshu
Liu,
Y.
Bai,
Ying
Yuan,
Xingya
Li,
Xiuwen
Wang,
Jia
Chen,
J.
Ying,
Xianjun
Yu,
S.
Qin,
Xianglin
Yuan,
Tao
Zhang,
Y.
Deng,
D.
Xiu,
Ying
Cheng,
M.
Tao,
R.
Jia,
Wei
Wang,
Jing
Li,
S.
Fan,
Mengye
Peng,
W.
Su
(2020)
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet. Oncology
-
Feng
Yang,
C.
Jin,
D.
Fu
(2014)
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
The New England journal of medicine, 371 16
-
S.
Liu,
Yi-long
Wu
(2020)
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
Expert Opinion on Investigational Drugs, 29
-
I.
Nagtegaal,
R.
Odze,
D.
Klimstra,
V.
Paradis,
M.
Rugge,
P.
Schirmacher,
K.
Washington,
F.
Carneiro,
I.
Cree
(2019)
The 2019 WHO classification of tumours of the digestive system
Histopathology, 76
-
P.
Sackstein,
Daniel
O'Neil,
A.
Neugut,
J.
Chabot,
T.
Fojo
(2018)
Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years.
Seminars in oncology, 45 4
-
J.
Xu,
Yan
Wang,
Yu
Chen,
R.
Jia,
Jie
Li,
J.
Gong,
Jing
Li,
Chuang
Qi,
Y.
Hua,
Cui
Tan,
Jian
Wang,
Ke
Li,
Y.
Sai,
Feng
Zhou,
Yongxin
Ren,
Weiguo
Qing,
Hong
Jia,
W.
Su,
L.
Shen
(2017)
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
Oncotarget, 8
-
Mariana
Gomes-Porras,
Jersy
CÁRDENAS-SALAS,
C.
Alvarez-Escola
(2020)
Somatostatin Analogs in Clinical Practice: A Review
International Journal of Molecular Sciences, 21
-
Deficiency of the macrophage growth factor journals
-
M.
Albertelli,
A.
Dotto,
F.
Nista,
A.
Veresani,
L.
Patti,
S.
Gay,
S.
Sciallero,
M.
Boschetti,
D.
Ferone
(2021)
Present and future of immunotherapy in Neuroendocrine Tumors
Reviews in Endocrine & Metabolic Disorders, 22
-
(2018)
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis
-
M.
Beyens,
T.
Vandamme,
M.
Peeters,
G.
Camp,
K.
Beeck
(2019)
Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors
Endocrine-related cancer, 26 3
-
S.
Krug,
T.
Gress,
P.
Michl,
A.
Rinke
(2017)
The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors
Digestion, 96
-
SM
Pyonteck,
BB
Gadea,
H.
Wang,
V.
Gocheva,
Kelsey
Hunter,
L.
Tang,
J.
Joyce
(2012)
Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development
Oncogene, 31
-
S.
Kopetz,
P.
Hoff,
Jeffrey
Morris,
R.
Wolff,
C.
Eng,
K.
Glover,
Rosie
Adinin,
M.
Overman,
V.
Valero,
S.
Wen,
C.
Lieu,
Shaoyu
Yan,
H.
Tran,
L.
Ellis,
J.
Abbruzzese,
J.
Heymach
(2010)
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
-
M.
Cives,
E.
Pelle’,
D.
Quaresmini,
F.
Rizzo,
M.
Tucci,
F.
Silvestris
(2019)
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications
Neuroendocrinology, 109
-
E.
Mitry,
T.
Walter,
E.
Baudin,
J.
Kurtz,
P.
Ruszniewski,
S.
Dominguez-Tinajero,
L.
Bengrine-Lefevre,
G.
Cadiot,
C.
Dromain,
F.
Farace,
P.
Rougier,
M.
Ducreux
(2014)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
European journal of cancer, 50 18
-
Satya
Das,
T.
Al-Toubah,
G.
El-Haddad,
J.
Strosberg
(2019)
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Expert Review of Gastroenterology & Hepatology, 13
-
Tetsuhide
Ito,
Lingaku
Lee,
R.
Jensen
(2016)
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
Expert Opinion on Pharmacotherapy, 17
-
4979 - Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (nets): results from the randomized phase III study (SANET-ep)
-
A.
Zurita,
M.
Khajavi,
H-K
Wu,
L.
Tye,
X.
Huang,
M.
Kulke,
H.
Lenz,
N.
Meropol,
W.
Carley,
S.
DePrimo,
E.
Lin,
X.
Wang,
C.
Harmon,
J.
Heymach
(2015)
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
British Journal of Cancer, 112
-
S.
Hasegawa,
N.
Kobayashi,
Naoki
Okubo,
M.
Tokuhisa,
A.
Goto,
Y.
Kurita,
Takamitsu
Sato,
K.
Hosono,
I.
Endo,
A.
Nakajima,
Y.
Ichikawa
(2020)
Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms
Internal Medicine, 60
-
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review
-
Jianming
Xu,
Jie
Li,
C.
Bai,
N.
Xu,
Zhiwei
Zhou,
Zhiping
Li,
Caicun
Zhou,
R.
Jia,
Ming
Lu,
Yue-juan
Cheng,
C.
Mao,
Wei
Wang,
K.
Cheng,
C.
Su,
Y.
Hua,
Chuang
Qi,
Jing
Li,
Wei
Wang,
Ke
Li,
Qiaoling
Sun,
Yongxin
Ren,
W.
Su
(2019)
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Clinical Cancer Research, 25
-
A.
Dasari,
Daneng
Li,
M.
Sung,
C.
Tucci,
J.
Kauh,
M.
Kania,
A.
Paulson
(2020)
Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
Journal of Clinical Oncology, 38
-
L.
Cai,
T.
Michelakos,
V.
Deshpande,
Kshitij
Arora,
Teppei
Yamada,
D.
Ting,
Marty
Taylor,
C.
Castillo,
A.
Warshaw,
K.
Lillemoe,
S.
Ferrone,
C.
Ferrone
(2019)
Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs)
Clinical Cancer Research, 25
-
A.
Dasari,
Chan
Shen,
D.
Halperin,
Bo
Zhao,
Shouhao
Zhou,
Ying
Xu,
T.
Shih,
James
Yao
(2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
JAMA Oncology, 3
-
A.
Rinke,
H.
Müller,
C.
Schade-Brittinger,
K.
Klose,
P.
Barth,
M.
Wied,
C.
Mayer,
B.
Aminossadati,
U.
Pape,
M.
Bläker,
J.
Harder,
C.
Arnold,
T.
Gress,
R.
Arnold
(2009)
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 28
-
Jinghong
Zhou,
Jun
Ni,
M.
Cheng,
Na
Yang,
Junqing
Liang,
L.
Ge,
Wei
Zhang,
Jia-Lin
Tang,
Qiaoling
Sun,
Fu-Rong
Li,
Jia
Hu,
D.
Shi,
Hongbo
Chen,
Jingwen
Long,
Junen
Sun,
Fangfang
Yin,
X.
Ge,
H.
Jia,
Fengmin
Zhou,
Yongxin
Ren,
Weiguo
Qing,
W.
Su
(2017)
Abstract 4187: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases
Cancer Research, 77
-
T.
Chan,
E.
O’Neill,
Christine
Habjan,
B.
Cornelissen
(2020)
Combination Strategies to Improve Targeted Radionuclide Therapy
Journal of Nuclear Medicine, 61
-
J.
Strosberg,
G.
El-Haddad,
E.
Wolin,
A.
Hendifar,
James
Yao,
B.
Chasen,
E.
Mittra,
P.
Kunz,
M.
Kulke,
H.
Jacene,
D.
Bushnell,
T.
O'Dorisio,
R.
Baum,
H.
Kulkarni,
M.
Caplin,
R.
Lebtahi,
T.
Hobday,
E.
Delpassand,
E.
Cutsem,
A.
Benson,
R.
Srirajaskanthan,
M.
Pavel,
J.
Mora,
J.
Berlin,
E.
Grande,
N.
Reed,
E.
Seregni,
K.
Öberg,
M.
Sierra,
P.
Santoro,
T.
Thevenet,
J.
Erion,
P.
Ruszniewski,
D.
Kwekkeboom,
E.
Krenning
(2017)
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
The New England Journal of Medicine, 376
-
James
Yao,
Manal
Hassan,
A.
Phan,
Cecile
Dagohoy,
C.
Leary,
J.
Mares,
E.
Abdalla,
J.
Fleming,
J.
Vauthey,
A.
Rashid,
Douglas
Evans
(2008)
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 18
-
M.
Pavel,
D.
O’Toole,
F.
Costa,
J.
Capdevila,
D.
Gross,
R.
Kianmanesh,
E.
Krenning,
U.
Knigge,
R.
Salazar,
U.
Pape,
K.
Öberg
(2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
Neuroendocrinology, 103
-
Yujie
Zhao,
A.
Adjei
(2015)
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
The oncologist, 20 6
-
S.
Krug,
J.
Mordhorst,
Fabian
Moser,
K.
Theuerkorn,
C.
Ruffert,
Maren
Egidi,
A.
Rinke,
T.
Gress,
P.
Michl
(2019)
Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
PLoS ONE, 14
-
A.
Yordanova,
H.
Ahrens,
G.
Feldmann,
P.
Brossart,
F.
Gaertner,
C.
Fottner,
M.
Weber,
H.
Ahmadzadehfar,
M.
Schreckenberger,
M.
Miederer,
M.
Essler
(2019)
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
Clinical Nuclear Medicine, 44
-
E.
Raymond,
L.
Dahan,
J.
Raoul,
Y.
Bang,
I.
Borbath,
C.
Lombard-Bohas,
J.
Valle,
P.
Metrakos,
Denis
Smith,
A.
Vinik,
Jen‐Shi
Chen,
D.
Hörsch,
P.
Hammel,
B.
Wiedenmann,
E.
Cutsem,
S.
Patyna,
D.
Lu,
C.
Blanckmeister,
R.
Chao,
P.
Ruszniewski
(2011)
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
The New England journal of medicine, 364 6
-
Lingaku
Lee,
Tetsuhide
Ito,
R.
Jensen
(2018)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Expert Opinion on Pharmacotherapy, 19
-
F.
Costa,
B.
Gumz
(2014)
Octreotide - A Review of its Use in Treating Neuroendocrine Tumours.
European endocrinology, 10 1